By M. Maurer
Read or Download Amyotrophic Lateral Sclerosis PDF
Similar neurology books
The invention of microRNAs has printed an unforeseen and amazing extra point of good tuning of the genome and the way genes are used repeatedly in numerous combos to generate the complexity that underlies for example the mind. because the preliminary stories played in C. elegans, we've long past a miles method to start to know how microRNA pathways may have an impression on overall healthiness and ailment in human.
It is a 3-in-1 reference ebook. It provides an entire scientific dictionary overlaying enormous quantities of phrases and expressions when it comes to hydrocephalus. It additionally provides vast lists of bibliographic citations. ultimately, it offers info to clients on tips to replace their wisdom utilizing a number of web assets.
- Case Studies in Sleep Neurology: Common and Uncommon Presentations
- Dystonia (World Federation of Neurology Seminars in Clinical Neurology, Volume 3)
- Benign Positional Vertigo: A Medical Dictionary, Bibliography, And Annotated Research Guide To Internet References
- Behavioral Treatment for Substance Abuse in People with Serious and Persistent Mental Illness: A Handbook for Mental Health Professionals
Additional info for Amyotrophic Lateral Sclerosis
NP001 has been tested in a phase I trial (NCT01091142) for safety and tolerability. It is currently evaluated in a subsequent phase II clinical trial (NCT01281631). 54 Olanzapine Olanzapine is an atypic neuroleptic drug used in psychiatry for the treatment of schizophrenia and other psychoses. One of its effects is also weight gain. In ALS patients, an involuntary weight loss of more than 10 percent of the original body weight correlates with an increased mortality. Thus treatment with olanzapine might increase the body weight, or, at least, keep it constant.
Measures and markers in amyotrophic lateral sclerosis. NeuroRx, Vol. 1, No. 2, pp. 273-283. R. J. (2009). Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler, Vol. 10, No. 2, pp. 99-106. , Goldstein, J. & Hulihan, J. (2003). A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology, Vol. 61, No. 4, pp. 456-464. D. B. (2006). Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol, Vol. 60, No. 1, pp. 22-31. , Wieland, S. R. (2008).
Prevalence of major depression in ALS: Comparison of a semi-structured interview and four self-report measures. Amyotroph Lateral Scler, Vol. 12, No. 4, pp. 297-302. A. B. (2007). Clinical presentation and diagnosis of Amyotrophic Lateral Sclerosis. NeuroRehabilitation, Vol. 22, pp. 409-416. , Malkus, B. & Cudkowicz, M. (2005). Tolerance of highdose (3,000 mg/day) coenzyme Q10 in ALS. Neurology, Vol. 65, No. 1, pp. 18341836. Foran, E. & Trotti, D. (2009). Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis by M. Maurer